Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans
Year of Publication
Zangwill, KM; Treanor, JJ; Campbell, JD; Noah, DL; Ryea, J.
J Infec Dis
Adult; Female; Immunization Schedule; Immunization-Secondary; Immunologic Memory; Influenza A Virus- H5N1 Subtype; Influenza Vaccines; Influenza- Human; Male; Middle Aged; Research NIH Extramural; Vaccines- Inactivated
Previously, we evaluated 2 doses of H5N1 influenza vaccine in persons 18-64 years of age (placebo and 7.5-, 15-, 45-, or 90-microg doses), separated by 28 days. In this study, 337 participants received a third dose, 6 months thereafter. Microneutralization (MN) and hemagglutination-inhibition geometric mean titers (GMTs) of antibody declined before the third dose. Twenty-eight days after the third dose, 78%, 67%, 43%, and 31% of recipients in the 90-, 45-, 15-, and 7.5-mug-dose groups had a MN GMT > or =1:40, respectively. Five months later, MN GMTs were significantly greater than those after the second dose.